Page 79 - Sohini Das

Astrazeneca-Sputnik jabs in combo show a better immune response: RDIF

Preliminary results from Azerbaijan trials have been announced

J&J seeks nod to start Covid vaccine trials on 12-17 age group in India

Studies show the US company's vaccine has 66 percent efficacy against preventing moderate to severe Covid-19.

Shapoorji Mistry and Dadachanji-led Kaisha Group to enter pharma space

Plans to launch brands in antacids, analgesics, blood thinners, bump up hiring

Single dose Sputnik Light shows 93.5% efficacy against Covid, claims RDIF

Sputnik Light tested on 320,000 subjects; no jab-related deaths; no cerebral vein thrombosis and no Guillain-Barre syndrome

Fortis posts Q1 profit of Rs 430 cr on revenue growth, exceptional gain

Revenue grows 132% in Q1FY22, with that from diagnostics putting up the best show

Wockhardt signs pact with Russian co to make 620 mn Sputnik doses in 2 yrs

This is twice the amount of doses Serum Institute of will make of the Russian shot, will take total Sputnik V capacity in India to 1.7 bn doses a year

Intense price competition in US generics market hits Indian pharma

Players say low prescription, double-digit price erosion are key reasons

Non-Covid biz not back to pre-pandemic levels: Metropolis Healthcare MD

In a Q&A, Ameera Shah says, however, that the impact of the second wave on her industry segment wasn't as bad as the first

Covid-19 pandemic: Novavax shot may get nod in India even before US

SII and Novavax have now completed submission of all modules required by regulatory agencies in India, Indonesia and the Philippines for the initiation of review of the vaccine

Availability of foreign Covid vaccines to get delayed over indemnity issue

India is not keen to grant indemnity to some players as it expects local availability to improve

Mylab partners with US firm to bring more point of care Covid tests

Mylab Discovery Solutions said that some tests will be launched by the end of this month and that these could be used at hotels, malls, multiplexes, offices, airports

DRL seeks a booster from Sputnik V but hurdles in scaling up remain

Even as the company investigates complaints of malpractice in the Ukraine, hurdles in scaling up the Russian vaccine remain the bigger challenge in the near term

J&J's single-dose Covid-19 vaccine gets approval for emergency use in India

J&J did not divulge details of when the vaccine will be available in India and what kind of initial volumes can be expected

J&J seeks approval for single-dose Covid-19 vaccine in India

It is not clear whether J&J is seeking indemnity against adverse events following vaccination like its US peers

Cipla's Q1 PAT grows 24% to Rs 715 crore riding on domestic sales

The company posted a 27% YoY increase in income from operations, at Rs 5,504 cr. Ebitda grew 28% to Rs 1,346 cr with a resulting Ebitda margin of 24.5%

India may soon have Covid-19 vaccines for children. All you need to know

Zydus Cadila DNA-plasmid vaccine is the prime contender. It has held trials on children aged 12 years and above

Gennova to use mRNA tech to develop vaccines for Zika, tuberculosis

mRNA vaccines typically have stringent temperature requirements to remain stable

USFDA okays Biocon insulin Semglee as first interchangeable biosimilar drug

Analysts expect additional revenues of 8 to 15 per cent for Biocon, with no competition in sight

AstraZeneca finds small clot risk after first dose of Vaxzevria vaccine

No extra risk after second dose shows study led and funded by drug maker

DRL stock falls 10% after missing Q1 estimates, probe by US SEC

The stock fell 10.4 per cent to Rs 4,844.35 (hitting the lower circuit) on Tuesday after reporting lower-than-expected quarterly earnings for Q1FY22